The Inspiration Behind the Innovation
While working in clinical research at a Veteran’s Administration pain clinic, NeuraLace founder and CEO Shiv Shukla got to know dozens of patients who were suffering from chronic nerve pain. Many patients had come to rely on opioids or turned to high-risk invasive procedures for temporary relief. Too many had lost hope for lasting relief or recovery after years of trying therapies that did not work or developing drug dependencies or other adverse effects, and physicians had few other options to offer them.
Shiv became singularly focused on finding a better alternative after electrical stimulation modalities had failed. He soon began to focus his research on magnetic stimulation -- honing in on its near immediate effectiveness at reducing pain and the long-term sustainability of its results. Magnetic pulse technology showed never-before-seen promise in the treatment of trauma-induced neuropathic pain.
After more than a decade of research, collaboration with a cross-section of the nation’s top pain experts, and support from a Board, leadership team and group of employees that shares Shiv’s passion and commitment, NeuraLace is excited to introduce Axon Therapy® as the first FDA-cleared targeted magnetic pulse therapy for chronic nerve pain as a major milestone in the company’s quest to create a pain-free tomorrow.